Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00837759

Enrollment

Registered

2009-02-05

Start date

2009-02-28

Completion date

2011-03-31

Last updated

2013-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diabetes, Diabetes Mellitus Type 1

Keywords

Type I Diabetes, Preserve Beta Cell Function, Sitagliptin, Lansoprazole, GAD65 (Diamyd), Diabetes, Type 1 Diabetes, T1DM

Brief summary

Background: * Type 1 diabetes (T1D) occurs when the immune system attacks insulin-producing cells (beta cells) in the pancreas, resulting in their death. * Insulin injections currently are the best method for controlling blood sugar in individuals with T1D. However, animal studies have shown that the drugs sitagliptin and lansoprazole can help reverse beta cell damage or develop new beta cells. In addition, Diamyd has been shown to weaken the immune process that attacks pancreatic beta cells. Objectives: * To find out whether a combination treatment of sitagliptin, lansoprazole, and Diamyd will help maintain functioning beta cells and/or cause new beta cells to form. * To determine how the drug combination affects insulin doses and blood sugar control. * To determine whether the drug combination affects the immune response involved in T1D.

Detailed description

Type 1 diabetes (T1D) is the end result of immune mediated beta-cell destruction. It is generally accepted that at the time of T1D is diagnosed, an individual has lost most (60-80%) of his/her beta cell function. The loss of insulin-producing beta cells is believed to occur over a period of months to years and individuals can retain some endogenous insulin production even years after clinical diagnosis of diabetes. The presence of residual beta cell mass may signify a complex interplay between the auto-destructive immune response and the capacity for limited beta cell regeneration. When initiated at T1D onset, immunosuppression has been shown to preserve beta cell function, but with significant and limiting toxicities. Selectively targeting the pathogenic T-cells involved in T1D development and progression could achieve the same objective with less toxicity. Various studies of the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes have demonstrated that administering glutamic acid decarboxylase (GAD65), a beta cell autoantigen, can prevent the immune destruction and delay or prevent diabetes onset. Preclinical studies have also identified several growth factors, including epidermal growth factor (EGF), glucagon-like peptide 1 (GLP-1), and gastrin, that appear to promote beta cell proliferation. We seek to test the potential for preserving beta cell function early in the disease course of T1D by combining antigen-specific immunomodulation with regenerative stimuli.

Interventions

DRUGInsulin

DRUGLansoprazole

DRUGSitagliptin

BIOLOGICALDiamyd

DRUGGAD65 (Diamyd)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 30 Years

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: 1. Recently diagnosed (within the preceding 4 months of screening) diabetes clinically consistent with T1D: A. Positive for anti-GAD antibody. B. BMI between 19 and 28 kg/m2; for those between the ages of 16 to 18, the BMI must be within 10th to 90th percentile for the age. 2. Ages between 16 and 30 years, inclusive 3. Random plasma C-peptide level of equal to or greater than 0.20 nmol/L 4. Willingness and ability to institute intensive insulin-based glucose management.

Exclusion criteria

1. Diabetic nephropathy with a creatinine clearance less than 60 cc/min or 24 hour urine albumin greater than 300 mg 2. Insulin requirements greater than 0.8 units/kg/day at the end of the run-in period 3. Regular use of a proton pump inhibitor within 3 months of enrollment 4. Use of GLP-1R agonist or DPP-4 inhibitor within 6 months prior to enrollment 5. Use of immunosuppressive therapy in the preceding 12 months 6. Evidence of chronic infection, for example, known human immunodeficiency virus (HIV) or hepatitis 7. History of any malignancy other than a treated basal or squamous skin cancer 8. Any chronic medical condition to unduly increase risk for the potential enrollee as judged by study investigators 9. Pregnancy, breastfeeding or planned pregnancy within two years, women of reproductive age not using an effective mode of contraception and unwilling to continue adequate contraception until 1 year after the last study drug administration 10. Any other co-existing condition/circumstances that would make patient unsuitable to participate in the study, as deemed by the investigators. For example, study investigators would exclude any potential candidate with any of the following (but the list is not inclusive): A. Clinically significant past history of an acute reaction to vaccines or other drugs B. Recent participation in other clinical trials with a new chemical entity C. A history of alcohol or drug abuse D. Significant neurological conditions like epilepsy, head trauma, or cerebrovascular accidents E. Individuals with significant gastrointestinal disorders determined by the study investigators to influence either study safety or data interpretation. Such conditions include but are not limited to gastroparesis and gastric bypass surgery F. Individuals with conditions prone to hypergastrinemia (Zollinger-Ellison syndrome, use of histamine-2 receptor blockers) or hypogastrinemia (gastric surgery).

Design outcomes

Primary

Measure	Time frame
Change in C-peptide	6 months following the protocol subject's randomization/treatment initiation

Secondary

Measure	Time frame
Glycemia Control (Change in HbA1c Level)	6 months following the protocol subject's randomization/treatment initiation
Change in Insulin Dose	6 months following the protocol subject's randomization/treatment initiation
Change in Anti-GAD Autoantibody Titers	6 months following the protocol subject's randomization/treatment initiation
Change in Anti-IA2 Titer	6 months following the protocol subject's randomization/treatment initiation
Change in ZnT8 Autoantibody Titer	6 months following the protocol subject's randomization/treatment initiation

Countries

United States

Participant flow

Participants by arm

Arm	Count
T1D Group Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.	7
Total	7

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Lost to Follow-up	1
Overall Study	Protocol Violation	3

Baseline characteristics

Characteristic	T1D Group
Age, Categorical <=18 years	1 Participants
Age, Categorical >=65 years	0 Participants
Age, Categorical Between 18 and 65 years	6 Participants
Age Continuous	21.9 years STANDARD_DEVIATION 3.2
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	0 Participants
Race (NIH/OMB) Black or African American	0 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	7 Participants
Region of Enrollment United States	7 participants
Sex: Female, Male Female	2 Participants
Sex: Female, Male Male	5 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	3 / 7
serious Total, serious adverse events	0 / 7